إعلان مُمول
Bharat Biotech in-licences GSK's Shigella vaccine candidate
نشر بتاريخ
Bharat Biotech has in-licensed GSK's Shigella vaccine candidate, altSonflex1-2-3, aimed at combating Shigellosis in young children in low- and middle-income countries. Following promising early-stage trials by GSK, Bharat Biotech will advance the vaccine through Phase-III trials, regulatory processes, and large-scale production. This collaboration strengthens Bharat Biotech's portfolio of vaccines against diarrheal infections.
البحث
الأقسام
- National
- International
- Business
- Technology
- Health
- التعليم
- Sports
- Entertainment
- Travel
- Environment
- Science
- Law
- Agriculture
- Real Estate
- Opinion
- Religion
- Weather
- Automotive
- Social Issues
- Culture
- Sci-Fi & Future
إقرأ المزيد
Saudi Arabia: No Umrah visa without approved hotel booking, what pilgrims must Know
Saudi Arabia has implemented a new policy, effective June 10, 2025, requiring all Umrah pilgrims...